Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/1/2023 | Buy → Hold | The Benchmark Company | |
| 2/17/2022 | $8.00 → $7.00 | Overweight | Cantor Fitzgerald |
| 11/16/2021 | $10.00 → $9.00 | Buy | Aegis Capital |
10-Q - VOLITIONRX LTD (0000093314) (Filer)
8-K - VOLITIONRX LTD (0000093314) (Filer)
S-3 - VOLITIONRX LTD (0000093314) (Filer)
Conference call to discuss financial and operational results scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev. , Nov. 14, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter of 2024. Volition management will host a conference call tomorrow, November 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Highlights Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 17 countries worldwid
Conference call to take place on Friday, November 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev., Nov. 8, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, November 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the third quarter 2024, in addition to providing a business update. Details of this event can be found below. Event: VolitionRx Limited Third Quarter 2024 Earnings and Business Update Conference Call Date: Friday, November 15, 2024 Time: 8:30 a.m. U.S. Eastern Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll free)Toll/Internati
Conference call to take place on Thursday August 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev., Aug. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announced it will host a conference call on Thursday, August 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the second quarter 2024, in addition to providing a business update. Details of this event can also be found below. Event: VolitionRx Limited Second Quarter 2024 Earnings and Business Update Conference Call Date: Thursday, August 15, 2024Time: 8:30 a.m. U.S. Eastern Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll free)Toll/Internati
SC 13G - VOLITIONRX LTD (0000093314) (Subject)
SC 13G - VOLITIONRX LTD (0000093314) (Subject)
SC 13G/A - VOLITIONRX LTD (0000093314) (Subject)
The Benchmark Company downgraded VolitionRx from Buy to Hold
Cantor Fitzgerald resumed coverage of VolitionRx with a rating of Overweight and set a new price target of $7.00 from $8.00 previously
Aegis Capital reiterated coverage of VolitionRX with a rating of Buy and set a new price target of $9.00 from $10.00 previously
HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his background includes extensive experience in designing and implementing highly focused commercial and business development
HENDERSON, Nev., Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024. Dr. Rubin has also been appointed as a member of the Audit Committee and the Compensation Committee. Dr. Rubin has over 20 years' experience within the life sciences sector, leading healthcare innovation and commercialization strategies for a wide range of organizations – from early-stage operations to large global corporate businesses
HENDERSON, Nev., July 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed PharmaVentures Ltd ("PharmaVentures"), a leading transaction advisory firm, to provide strategic advice and transactional support on the out-license of Volition's expanding oncology portfolio. PharmaVentures has been engaged to act as an advisor to Volition to help secure licensing deals with industry leaders for both Nu.Q® Cancer – a range of simple blood-based assays to help detect, guide treatment, and monitor cancer, and Capture-PCR™ – a novel detection method for liquid biopsy in cancer and potentially other diseases. Gael Forterre, Chief Commer
4 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
3 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
Conference call to discuss financial and operational results scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev. , Nov. 14, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter of 2024. Volition management will host a conference call tomorrow, November 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Highlights Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 17 countries worldwid
Conference call to take place on Friday, November 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev., Nov. 8, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, November 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the third quarter 2024, in addition to providing a business update. Details of this event can be found below. Event: VolitionRx Limited Third Quarter 2024 Earnings and Business Update Conference Call Date: Friday, November 15, 2024 Time: 8:30 a.m. U.S. Eastern Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll free)Toll/Internati
HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his background includes extensive experience in designing and implementing highly focused commercial and business development
EF Hutton analyst Tim Moore maintains VolitionRX (AMEX:VNRX) with a Buy and maintains $4 price target.
Cantor Fitzgerald analyst Ross Osborn reiterates VolitionRX (AMEX:VNRX) with a Overweight and maintains $2.5 price target.